NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis → Bill Gates is all about this tiny $2 stock (From Timothy Sykes) (Ad) Free TLSI Stock Alerts $9.85 +0.15 (+1.55%) (As of 05/17/2024 06:55 PM ET) Add Compare Share Share Today's Range$9.52▼$9.8950-Day Range$9.07▼$10.2552-Week Range$3.32▼$16.24Volume5,000 shsAverage Volume35,131 shsMarket Capitalization$263.59 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get TriSalus Life Sciences alerts: Email Address TriSalus Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.4% Upside$16.00 Price TargetShort InterestHealthy7.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.16 out of 5 starsMedical Sector332nd out of 914 stocksSurgical & Medical Instruments Industry47th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingTriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.13% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 38.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLSI. Previous Next 1.8 News and Social Media Coverage News SentimentTriSalus Life Sciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for TriSalus Life Sciences this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders76.20% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Previous Next N/A Earnings and Valuation Read more about TriSalus Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs About TriSalus Life Sciences Stock (NASDAQ:TLSI)TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More TLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSI Stock News HeadlinesMay 16, 2024 | seekingalpha.comTLSI TriSalus Life Sciences, Inc.May 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024May 15, 2024 | businesswire.comTriSalus Reports Q1 2024 Financial Results and Business UpdateMay 13, 2024 | americanbankingnews.comTriSalus Life Sciences (TLSI) to Release Quarterly Earnings on WednesdayMay 12, 2024 | americanbankingnews.comTriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at JonestradingMay 11, 2024 | msn.comJonesTrading Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationMay 11, 2024 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Drop in Short InterestMay 7, 2024 | businesswire.comTriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsMay 6, 2024 | businesswire.comTriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference CallApril 30, 2024 | businesswire.comTriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth InitiativesApril 5, 2024 | morningstar.comTriSalus Life Sciences IncApril 3, 2024 | benzinga.comTriSalus Life Sciences Stock (NASDAQ:TLSI), Earnings Estimates, EPS, and RevenueApril 2, 2024 | insidermonkey.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call TranscriptApril 1, 2024 | markets.businessinsider.comTriSalus Life Sciences, Inc. Q4 sales increaseApril 1, 2024 | finance.yahoo.comTriSalus Reports Q4 and Full Year 2023 Financial Results and Business UpdateApril 1, 2024 | finance.yahoo.comTriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ...March 26, 2024 | finance.yahoo.comTriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific MeetingMarch 21, 2024 | finance.yahoo.comTriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific MeetingMarch 11, 2024 | businesswire.comTriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101March 7, 2024 | businesswire.comTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101February 29, 2024 | businesswire.comTriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver TumorsJanuary 24, 2024 | seekingalpha.comTriSalus Life Sciences: Rocket-Like Recovery Could Be An Inflection PointJanuary 9, 2024 | morningstar.comTriSalus Life Sciences Inc TLSISee More Headlines Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/20/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+62.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net MarginsN/A Pretax Margin-368.27% Return on EquityN/A Return on Assets-221.65% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.71 Sales & Book Value Annual Sales$18.51 million Price / Sales14.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.98) per share Price / Book-10.05Miscellaneous Outstanding Shares26,760,000Free Float6,368,000Market Cap$263.59 million OptionableNot Optionable Beta0.66 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Mary T. Szela B.S.N. (Age 60)M.B.A., CEO, President & Director Comp: $880.67kMr. Sean Edward Murphy (Age 71)CFO & Director Comp: $628.75kDr. Steven C. Katz F.A.C.S. (Age 49)M.D., Chief Medical Officer & Chairman of Scientific Advisory Board Comp: $849.89kMs. Jodi Devlin (Age 62)President of Commercial Operations Mr. Alan C. MendelsonSecretaryKey CompetitorsSight SciencesNASDAQ:SGHTInovio PharmaceuticalsNASDAQ:INOAngioDynamicsNASDAQ:ANGOUtah Medical ProductsNASDAQ:UTMDNeuroPaceNASDAQ:NPCEView All CompetitorsInstitutional OwnershipAnson Capital Inc.Sold 10,590 shares on 5/7/2024Ownership: 0.091%Connecticut Wealth Management LLCSold 12,582 shares on 5/1/2024Ownership: 0.167%Tyche Wealth Partners LLCSold 16,664 shares on 4/23/2024Ownership: 0.037%View All Institutional Transactions TLSI Stock Analysis - Frequently Asked Questions Should I buy or sell TriSalus Life Sciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TriSalus Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TLSI shares. View TLSI analyst ratings or view top-rated stocks. What is TriSalus Life Sciences' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for TriSalus Life Sciences' shares. Their TLSI share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 62.4% from the stock's current price. View analysts price targets for TLSI or view top-rated stocks among Wall Street analysts. How have TLSI shares performed in 2024? TriSalus Life Sciences' stock was trading at $8.45 on January 1st, 2024. Since then, TLSI shares have increased by 16.6% and is now trading at $9.85. View the best growth stocks for 2024 here. When is TriSalus Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our TLSI earnings forecast. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its quarterly earnings data on Monday, April, 1st. The company reported ($1.56) earnings per share for the quarter. The company had revenue of $5.72 million for the quarter. What guidance has TriSalus Life Sciences issued on next quarter's earnings? TriSalus Life Sciences updated its FY 2024 earnings guidance on Thursday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.8 million-. Who are TriSalus Life Sciences' major shareholders? TriSalus Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Connecticut Wealth Management LLC (0.17%), Anson Capital Inc. (0.09%) and Tyche Wealth Partners LLC (0.04%). How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLSI) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
